These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2422548)

  • 21. [The role of cytokines in viral infections].
    Cavallo R; Cavallo F; Cavallo G
    G Batteriol Virol Immunol; 1994; 86(1-12):65-78. PubMed ID: 8706977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Passive and active immunoprophylaxis of hepatitis B.
    Seeff LB; Koff RS
    Gastroenterology; 1984 May; 86(5 Pt 1):958-81. PubMed ID: 6231210
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunoglobulins and rules of passive-active prophylaxis].
    Bucholc B
    Przegl Epidemiol; 2003; 57(2):391-7. PubMed ID: 12910611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein.
    Kita H; Moriyama T; Kaneko T; Harase I; Nomura M; Miura H; Nakamura I; Yazaki Y; Imawari M
    Hepatology; 1993 Nov; 18(5):1039-44. PubMed ID: 7693568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Booster vaccinations: can immunologic memory outpace disease pathogenesis?
    Pichichero ME
    Pediatrics; 2009 Dec; 124(6):1633-41. PubMed ID: 19933727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future options for the management of hepatitis C.
    Davis GL; Nelson DR; Reyes GR
    Semin Liver Dis; 1999; 19 Suppl 1():103-12. PubMed ID: 10349698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for HCV infection: next steps.
    Lang K; Weiner DB
    Expert Rev Vaccines; 2008 Sep; 7(7):915-23. PubMed ID: 18767942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular immunotherapy for viral infection after HSC transplantation.
    Moss P; Rickinson A
    Nat Rev Immunol; 2005 Jan; 5(1):9-20. PubMed ID: 15630425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune reconstitution in HIV-1-infected patients.
    Imami N; Hardy G; Pires A; Burton C; Pido-Lopez J; Mela C; Gotch F
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1138-45. PubMed ID: 12211404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral immune regulation: a novel method for modulation of anti-viral immunity.
    Margalit M; Ilan Y
    J Clin Virol; 2004 Dec; 31 Suppl 1():S63-8. PubMed ID: 15567096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Future therapies for hepatitis C.
    Pawlotsky JM; Gish RG
    Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral vaccines and antiviral drugs. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1983; 693():1-72. PubMed ID: 6197821
    [No Abstract]   [Full Text] [Related]  

  • 37. Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant.
    von Herrath MG; Coon B; Wolfe T
    J Autoimmun; 2001 May; 16(3):193-9. PubMed ID: 11334483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
    Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC
    Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunologic interactions between virus and host].
    Kaaden OR; Stolze B; Haas L
    Dtsch Tierarztl Wochenschr; 1987 Apr; 94(4):225-7. PubMed ID: 2439272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.